These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 37207881)

  • 1. Integrated network pharmacology, transcriptomics, and metabolomics analysis to reveal the mechanism of salt Eucommiae cortex in the treatment of chronic kidney disease mineral bone disorders via the PPARG/AMPK signaling pathway.
    Shen J; Liu Y; Wang Q; Chen H; Hu Y; Guo X; Liu X; Li Y
    J Ethnopharmacol; 2023 Oct; 314():116590. PubMed ID: 37207881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Research into the anti-pulmonary fibrosis mechanism of Renshen Pingfei formula based on network pharmacology, metabolomics, and verification of AMPK/PPAR-γ pathway of active ingredients.
    Yan L; Jiang MY; Fan XS
    J Ethnopharmacol; 2023 Dec; 317():116773. PubMed ID: 37308028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of triangle grass decoction on bone metabolism in rats with chronic kidney disease complicated with mineral and bone abnormalities.
    Liu L; Wang L; Li L; Wang H; Yuan L; Kang L; Jiang Q; Chen G; Lv N; Cui X; Huang L; Wu H; Xu J; Li Y
    J Ethnopharmacol; 2021 Jul; 275():114126. PubMed ID: 33872749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
    Meng Y; Zhang H; Li Y; Li Q; Zuo L
    Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Advanced Glycation End-Products (AGE) Lowering Drug ALT-711 on Biochemical, Vascular, and Bone Parameters in a Rat Model of CKD-MBD.
    Chen NX; Srinivasan S; O'Neill K; Nickolas TL; Wallace JM; Allen MR; Metzger CE; Creecy A; Avin KG; Moe SM
    J Bone Miner Res; 2020 Mar; 35(3):608-617. PubMed ID: 31743501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fucoidan Ameliorates Renal Injury-Related Calcium-Phosphorus Metabolic Disorder and Bone Abnormality in the CKD-MBD Model Rats by Targeting FGF23-Klotho Signaling Axis.
    Liu BH; Chong FL; Yuan CC; Liu YL; Yang HM; Wang WW; Fang QJ; Wu W; Wang MZ; Tu Y; Wan ZY; Wan YG; Wu GW
    Front Pharmacol; 2020; 11():586725. PubMed ID: 33708111
    [No Abstract]   [Full Text] [Related]  

  • 7. Dietary interventions for mineral and bone disorder in people with chronic kidney disease.
    Liu Z; Su G; Guo X; Wu Y; Liu X; Zou C; Zhang L; Yang Q; Xu Y; Ma W
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD010350. PubMed ID: 26376110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The WNT/β-catenin system in chronic kidney disease-mineral bone disorder syndrome.
    Zhang L; Adu IK; Zhang H; Wang J
    Int Urol Nephrol; 2023 Oct; 55(10):2527-2538. PubMed ID: 36964322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A meta-analysis of randomized controlled trials of tonifying kidney and strengthen bone therapy on nondialysis patients with chronic kidney disease-mineral and bone disorder.
    Wu G; Li L; Wu Z
    Medicine (Baltimore); 2023 Jun; 102(25):e34044. PubMed ID: 37352066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor necrosis factor-alpha is associated with mineral bone disorder and growth impairment in children with chronic kidney disease.
    Meza K; Biswas S; Zhu YS; Gajjar A; Perelstein E; Kumar J; Akchurin O
    Pediatr Nephrol; 2021 Jun; 36(6):1579-1587. PubMed ID: 33387018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative comparison of chronic kidney disease-mineral and bone disorder rat models.
    Zhang X; Li T; Wang L; Li Y; Ruan T; Guo X; Wang Q; Meng X
    Front Physiol; 2023; 14():1083725. PubMed ID: 36818435
    [No Abstract]   [Full Text] [Related]  

  • 12. Dentoalveolar Alterations in an Adenine-Induced Chronic Kidney Disease Mouse Model.
    Mohamed FF; Amadeu de Oliveira F; Kinoshita Y; Yalamanchili RR; Eltilib LA; Andras NL; Narisawa S; Tani T; Chu EY; Millán JL; Foster BL
    J Bone Miner Res; 2023 Aug; 38(8):1192-1207. PubMed ID: 37191192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients.
    Karaboyas A; Muenz D; Fuller DS; Desai P; Lin TC; Robinson BM; Rossetti S; Pisoni RL
    Am J Kidney Dis; 2022 Mar; 79(3):362-373. PubMed ID: 34273436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a quantitative systems pharmacology model of chronic kidney disease: metabolic bone disorder.
    Gaweda AE; McBride DE; Lederer ED; Brier ME
    Am J Physiol Renal Physiol; 2021 Feb; 320(2):F203-F211. PubMed ID: 33308018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivation of Osteoblast PKC Signaling Reduces Cortical Bone Mass and Density and Aggravates Renal Osteodystrophy in Mice with Chronic Kidney Disease on High Phosphate Diet.
    Zaloszyc A; Choquet P; Sayeh A; Bartosova M; Schaefer B; Huegel U; Aubertin-Kirch G; Healy C; Severac F; Rizzo S; Boivin G; Schaefer F; Fischbach M; Bacchetta J; Bahram S; Schmitt CP
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Management of bone and mineral metabolism disorders before the dialysis stage remains still perfectible. Data from the French Phosphorus and Calcium Survey Photo-Graphe].
    Jean G; Daugas É; Roth H; Drueke T; Bouchet JL; Hannedouche T; London G; Fouque D
    Nephrol Ther; 2017 Nov; 13(6):470-478. PubMed ID: 28843391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ferric citrate and intravenous iron sucrose on markers of mineral, bone, and iron homeostasis in a rat model of CKD-MBD.
    Biruete A; Metzger CE; Chen NX; Swallow EA; Vrabec C; Clinkenbeard EL; Stacy AJ; Srinivasan S; O'Neill K; Avin KG; Allen MR; Moe SM
    Nephrol Dial Transplant; 2022 Sep; 37(10):1857-1867. PubMed ID: 35482713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The intervention effect of zuogui pill on chronic kidney disease-mineral and bone disorder regulatory factor.
    Ma X; He L
    Biomed Pharmacother; 2018 Oct; 106():54-60. PubMed ID: 29957466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Plant-Based Protein Consumption on Kidney Function and Mineral Bone Disorder Outcomes in Adults With Stage 3-5 Chronic Kidney Disease: A Systematic Review.
    Burstad KM; Cladis DP; Wiese GN; Butler M; Hill Gallant KM
    J Ren Nutr; 2023 Nov; 33(6):717-730. PubMed ID: 37116624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.